Multi-omics characterization of RNA binding proteins reveals disease comorbidities and potential drugs in COVID-19

https://doi.org/10.1016/j.compbiomed.2023.106651Get rights and content
Under a Creative Commons license
open access

Highlights

  • Transcriptomic and proteomic profiles of 178 COVID-19 patients were profiled and analyzed.

  • RNA binding proteins were likely to be perturbed in infection and interacting with viral proteins.

  • Interactome analysis revealed that RBPs were likely to locate in central regions of network.

  • Network analysis revealed disease comorbidities and potential drugs in COVID-19.

Abstract

The COVID-19 has led to a devastating global health crisis, which emphasizes the urgent need to deepen our understanding of the molecular mechanism and identifying potential antiviral drugs. Here, we comprehensively analyzed the transcriptomic and proteomic profiles of 178 COVID-19 patients, ranging from asymptomatic to critically ill. Our analyses found that the RNA binding proteins (RBPs) were likely to be perturbed in infection. Interactome analysis revealed that RBPs interact with virus proteins and the viral interacting RBPs were likely to locate in central regions of human protein-protein interaction network. Functional enrichment analysis revealed that the viral interacting RBPs were likely to be enriched in RNA transport, apoptosis and viral genome replication-related pathways. Based on network proximity analyses of 299 human complex-disease genes and COVID-19-related RBPs in the human interactome, we revealed the significant associations between complex diseases and COVID-19. Network analysis also implicated potential antiviral drugs for treatment of COVID-19. In summary, our integrative characterization of COVID-19 patients may thus help providing evidence regarding pathophysiology and potential therapeutic strategies for COVID-19.

Keywords

COVID-19
RNA binding proteins
Network analysis
Potential drugs

Cited by (0)

1

These authors contribute equally to this work.